Changes of visual acuity and area of CNVM after follow up
| Treatment group | Control group | p Value | |
| No of patients | 20 | 19 | |
| Duration of follow up (months) | 27.2 (4.6) (24 to 36) | 28.9 (5.2) (24 to 38) | 0.2859 |
| Area of CNVM (mm2) | |||
| Baseline | 1.472 (1.055) (0.221 to 3.554) | 1.549 (1.065) (0.105 to 3.331) | 0.8218 |
| 3 months | 1.584 (1.097) (0.245 to 3.983) | 1.956 (1.332) (0.235 to 4.244) | 0.3488 |
| 6 months | 1.601 (1.102) (0.287 to 4.488) | 2.133 (1.367) (0.332 to 5.301) | 0.1880 |
| 12 months | 1.619 (1.122) (0.301 to 4.807) | 2.201 (1.439) (0.406 to 5.396) | 0.1661 |
| 24 months | 1.317 (1.435) (0.422 to 5.533) | 2.717 (1.974) (0.496 to 7.395) | 0.0153 |
| Change of area of CNVM | |||
| 3 months | 117.61 (78.36) % (78 to 188 %) | 136.28 (80.28) % (83 to 287 %) | 0.4670 |
| 6 months | 138.76 (84.22) % (71 to 245 %) | 156.35 (87.72) % (83 to 332 %) | 0.5271 |
| 12 months | 144.67 (94.59) % (54 to 351 %) | 208.37 (98.32) % (78 to 411 %) | 0.2823 |
| 24 months | 154.87 (156.49) % (35 to 632 %) | 248.84 (123.83) % (77 to 472 %) | 0.0452 |
| Eyes with change of area of CNVM 24 months after the start of the follow up | |||
| Decreased (⩾20%) | 7 eyes (35 %) | 1 eyes (5 %) | |
| Unchanged | 6 eyes (30 %) | 4 eyes (21 %) | |
| Increased (⩾20%) | 7 eyes (35 %) | 14 eyes (74 %) | |
| Area of CNVM 24 months after the start of the follow up | |||
| 0–0.250 mm2 | 1 eye (5%) | 0 eye (0%) | |
| 0.251–0.500 mm2 | 3 eyes (15%) | 1 eye (5%) | |
| 0.501–1.000 mm2 | 4 eyes (20%) | 4 eyes (21%) | |
| 1.001–2.000 mm2 | 9 eyes (45%) | 4 eyes (21%) | |
| 2.001–3.000 mm2 | 2 eyes (10%) | 2 eyes (11%) | |
| 3.001–4.000 mm2 | 0 eye (0%) | 3 eyes (16%) | |
| 4.001–5.000 mm2 | 1 eye (5%) | 2 eyes (11%) | |
| >5.000 mm2 | 0 eye (0%) | 1 eye (5%) | |
| Visual acuity | |||
| Baseline | 0.111 (22.2/200) (0.01 to 0.4) | 0.141 (34.2/200) (0.02 to 0.4) | |
| LogMAR | 0.958 (0.470) | 0.851 (0.403) | |
| 3 months | 0.120 (24/200) (0.02 to 0.4) | 0.120 (24/200) (0.03 to 0.4) | |
| LogMAR | 0.922 (0.362) | 0.921 (0.394) | |
| 6 months | 0.108 (21.6/200) (0.02 to 0.4) | 0.106 (21.2/200) (0.04 to 0.4) | |
| LogMAR | 0.964 (0.333) | 0.971 (0.319) | |
| 12 months | 0.091 (18.2/200) (0.02 to 0.6) | 0.089 (17.8/200) (0.01 to 0.2) | |
| LogMAR | 1.006 (0.338) | 1.049 (0.278) | |
| 24 months | 0.086 (19.2/200) (0.02 to 0.6) | 0.063 (12.6/200) (0.01 to 0.2) | |
| LogMAR | 0.977 (0.353) | 1.198 (0.264) | |
| Change of logMAR visual acuity after the start of the follow up | |||
| 3 months | −0.035 (0.262) (−0.602 to +0.523) | +0.070 (0.237) (−0.699 to +0.477) | 0.1982 |
| 6 months | +0.007 (0.365) (−0.477 to +0.903) | +0.120 (0.253) (−0.699 to +0.) | 0.2708 |
| 12 months | +0.048 (0.426) (−0.477 to +1.125) | +0.198 (0.290) (−0.301 to +0.699) | 0.2090 |
| 24 months | +0.019 (0.443) (−0.477 to 1.301) | +0.347 (0.374) (−0.477 to +0.602) | 0.0173 |
| Eyes with change of visual acuity during 24 months | |||
| Improved (⩾2 lines) | 9 eyes (45 %) | 3 eyes (16 %) | |
| Unchanged | 4 eyes (20 %) | 3 eyes (16 %) | |
| Deteriorated (⩾2 lines) | 7 eyes (35%) | 13 eyes (68%) | |
| Visual acuity 24 months after the start of the follow up | |||
| ⩾0.6 (120/200) | 1 eye (5%) | 0 eye (0%) | |
| 0.1 to 0.5 (20/200 to 100/200) | 12 eyes (60%) | 5 eyes (26%) | |
| 0.06 to 0.09 (12/200 to 18/200) | 3 eyes (15%) | 4 eyes (21%) | |
| 0.01 to 0.05 (2/200 to 10/200) | 4 eyes (20%) | 10 eyes (53%) | |
LogMAR of visual acuity = logarithm of the minimal angle resolution of visual acuity. CNVM = choroidal neovascular membrane.